Locations
Intercell AG operates in three countries with headquarters in Vienna, manufacturing facilities in Scotland and R&D facilities in the U.S. (Maryland).
The company, founded as a spin-off from Vienna University in 1997, is today one of the most innovative players in the field of novel vaccines. With its location in three different countries, Intercell is an international company with a workforce of approximately 400 colleagues from more than 30 different countries.
Intercell’s headquarters consists of more than 220 employees engaged in research and development and administration, including finance, marketing and sales.
Intercell USA, with more than 100 employees, focuses on discovery and development of vaccines, administered via a novel needle-free patch.
Intercell’s manufacturing site in Scotland, with close to 80 employees, produces the vaccine candidate against Japanese Encephalitis. The site has development and commercial manufacturing capacities.